Nitroxoline (Asieris Pharmaceuticals)

硝羟喹啉 (亚虹医药)

Report date: 2025/01/10 10:30:33

Base Information

Drug NameNitroxoline (Asieris Pharmaceuticals)
Drug Alias Namenitroxolinum唯施可VesiqueAPL-1202
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMethionine aminopeptidase 2 inhibitorsAngiogenesis inhibitors
TargetsMethionine aminopeptidase 2
Therapy Area/IndicationsUrinary Bladder NeoplasmsAmebiasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesJohns Hopkins University
China Registration ClassN/A

Develop Information

Active IndicationsUrinary Bladder NeoplasmsAmebiasis
Inactive IndicationsN/A

Other Information

ATC CodeJ01XX07